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A-77003, a human immunodeficiency virus type 1 (HIV-1) protease inhibitor, is effective for both acute and
chronic infection in vitro and was evaluated clinically by continuous intravenous infusion administration. The
minimum effective dose (the concentration required to completely inhibit viral replication) was determined in
vitro in a population of uninfected (99%) and HIV-infected (1%) cells exposed to A-77003 by continuous
infusion in hollow-fiber bioreactors. The production of infectious HIV and release of p24 antigen from infected
cells were completely inhibited in cultures exposed to A-77003 at or above a concentration of 0.5 mM.
Measurement of unintegrated HIV-1 DNA synthesis and flow cytometric analysis for cells expressing HIV p24
antigen demonstrated that the spread of HIV to uninfected cells was also blocked at 0.5 mM A-77003. Dose
deescalation to 0.25 mM or removal of A-77003 resulted in the limited spread of the virus throughout the
culture, the resumption of viral DNA synthesis, and release of p24. HIV produced after exposure to 0.5 mM
A-77003 was noninfectious for a period of 72 h after the removal of the drug. Addition of 1 mg of a1-acid
glycoprotein per ml to this in vitro system completely ablated the anti-HIV effect of 0.5 mMA-77003. These data
suggest that determination of the minimum effective dose under conditions which simulate human pharma-
codynamic patterns may be useful in determining the initial dose and schedule for clinical trials. However,
other factors, such as serum protein binding, may influence the selection of a therapeutic regimen.
Human immunodeficiency virus (HIV) encodes an aspartic
proteinase which, as a homodimer, posttranslationally and pro-
teolytically cleaves the viral gag and pol gene precursors to the
mature viral proteins (16, 24). Site-specific mutagenesis of the
HIV protease or inhibition of the enzyme with specific inhib-
itors results in the production of noninfectious virions which
have the morphological features of immature particles (4, 7,
14, 17). The critical role of protease in virus maturation has
established the HIV protease as an important target for ther-
apeutic intervention during the late (postintegration) phase of
HIV replication. HIV protease was both cloned and chemically
synthesized, and the resultant structural information (18–20)
led to the development of substrate analogs with exquisite
substrate specificity (6, 12, 25). Earlier studies had indicated
that A-77003, a symmetric inhibitor of the HIV protease, had
antiviral activity at submicromolar levels against a spectrum of
HIV strains and an excellent therapeutic index in primary and
transformed human cell lines (11, 15).
Interest in whether the in vitro activity of A-77003 would
also result in clinical efficacy led to preclinical and clinical
studies of this compound. We have developed an in vitro test
system which is based upon hollow-fiber (HF) technology and
has the following attributes: (i) it is able to grow and maintain
cells at near tissue densities, (ii) it provides access for serial
evaluation of drug exposure, metabolism, and efficacy, and (iii)
it permits the exposure of a defined cell population to a con-
centration-time profile of antiretroviral agents identical to that
achievable in humans. In this study, we have utilized this HF
pharmacodynamic model system to determine a minimum ef-
fective dose for A-77003 in vitro, given the continuous infusion
mode of administration.
MATERIALS AND METHODS
Cell culture. Human T-lymphoblastoid cell lines obtained from the AIDS
Research and Reference Reagent Program (National Institute of Allergy and
Infectious Diseases, Bethesda, Md.) were cultured as described previously (1b).
HF units (Cellco Inc., Germantown, Md.) were initiated by the addition of a
1:100 mixture of HIVIIIB-infected (CEM-H9IIIB) and uninfected CEM cells
(3.5 3 107 cells per unit) to the extracapillary space (ECS). The percentage of
infected cells was determined by flow cytometry of methanol-fixed, permabilized
cells with fluorescein isothiocyanate-conjugated anti-p24 (15). In continuous
infusion experiments, the drug-containing medium was recirculated and replen-
ished daily.
Drugs and compounds.A-77003 was provided by Abbott Laboratories (Abbott
Park, Ill.). The concentrations of A-77003 used in HF studies were monitored by
bioassay. Human a1-acid glycoprotein (a1-AGP; G-9885; purity, 99%) was pur-
chased from Sigma Chemical Company (St. Louis, Mo.).
HIV antigen assay. HIV gag p24 protein in cell-free culture supernatants was
measured by the Coulter p24 enzyme-linked immunosorbent assay (ELISA)
(Coulter Immunology, Hialeah, Fla.) as described previously (1b).
DNA PCR. High- and low-molecular-weight DNA was isolated (8), and a PCR
with the SK38 and SK39 primers (21) was performed as described previously
(1b).
HIV infectivity assays. The titers of the infectious HIV were determined with
CD4-transfected HeLa cell line 1022 (3). The residual drug was reduced by
dilution (or by addition of a1-AGP at 1 mg/ml) to a concentration which did not
inhibit HIV. The cytotoxicity of HIV type 1 (HIV-1) in the presence and absence
of A-77003 was correlated to the formation of formazan in a 3-(4,5-dimethyl-
thiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay as previously de-
scribed (15).
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Concentration response analysis. We measured the release
of p24 from a 1:100 mixture of infected and uninfected CEM
cells treated with 0 to 25 mM A-77003 in microwell plates. The
50% effective concentration (EC50) was calculated to be 0.124
mM, which is similar to data presented earlier (2, 15) on the
EC50 for treatment of acute infection of fresh human periph-
eral blood lymphocytes and several cell lines (e.g., MT-2). The
EC50s of A-77003 for several of the HIV-1 strains that we
tested, i.e., MN and several clinical isolates, including the
zidovudine-resistant strain G910-11, were similar (data not
shown).
HF pharmacodynamics. Both animal and human pharma-
cokinetic data (oral bioavailability for humans, ,2%) indi-
cated that A-77003 would be best administered by continuous
infusion (1). Therefore, we determined the minimal effective
dose by exposure of 1:100 mixtures of infected and uninfected
CEM cells to various doses of A-77003 in a simulated constant
infusion as described previously (1b). The continuous infusion
regimen was simulated by addition of A-77003 at the indicated
concentration to the medium circulating in the central reser-
voir. Figure 1 shows the effect of continuous exposure of HIV-
infected cells to 0.063, 0.125, and 0.25 mM A-77003 (0.5-, 1-,
and 2-fold the EC50, respectively) on p24 levels in the cell-free
culture medium in the ECS. Exposure to the drug was main-
tained for a total of 11 days. While each of the treated cultures
showed some suppression of p24 release, HIV was actively
replicating in the culture, as judged by the slow progressive
increase in p24 levels in the cell-free medium removed from
the ECS of the bioreactor. Further analysis of the cells in the
ECS of the treated bioreactors by flow cytometry indicated that
HIV was able to spread to uninfected cells. At day 11, un-
treated cultures had approximately 63% infected cells, while
those treated with 0.063, 0.125, and 0.25 mM A-77003 had 60,
58, and 28% p24-positive cells, respectively. The viability of the
cells in each of the HF bioreactors was greater than 85% as
determined by trypan blue dye exclusion, and cells were ac-
tively growing, as measured by increased glucose utilization
and lactate production.
In order to determine a drug concentration which effectively
limited HIV infection and spread of the virus, 1:100 HIV-
infected-to-uninfected CEM cell mixtures were exposed to 0,
0.5, 1, and 2 mM A-77003. Assay of the cell-free medium by a
p24 antigen ELISA indicated that while p24 rapidly increased
in the untreated cells, little to no p24 was released from cells
treated with concentrations 4-, 8-, and 16-fold the EC50 of
A-77003 (Fig. 2). High copy numbers of unintegrated DNA are
usually associated with active HIV-1 DNA synthesis and acute
infections (1b, 5, 13, 22). Linear and circular forms of uninte-
grated HIV proviral DNA are not pelleted by the Hirt DNA
extraction, while integrated proviral DNA is associated with
the bulk of chromosomal DNA in the pellet. Analysis of un-
integrated HIV-1 DNA by PCR amplification of DNA in the
Hirt supernatants indicated that HIV-1 was actively replicating
in untreated cells and cells treated with two times the EC50 but
not in cells treated with four times the EC50 (Fig. 3). Thus,
A-77003, at concentrations of 0.5 mM and above, was able to
prevent the de novo replication of HIV in HF bioreactors. The
findings of flow cytometric analysis were consistent with these
FIG. 1. The effect of continuous exposure of HIV-infected cells to A-77003
at 0.5-, 1-, and 2-fold the EC50. Four HF bioreactors were set with 107 CEM cells
and 105 CEM-H9IIIB cells (infected-to-uninfected ratio, 1:100). The four biore-
actors were set in parallel, and the cells were continuously exposed to medium
with A-77003 concentrations 0.5-, 1-, and 2-fold the EC50 (0.063 [1], 0.125 [{],
and 0.25 [] mM A-77003) and to medium without the drug (n). Samples were
taken from the ECS at the indicated time points, and p24 in the cell-free culture
medium was measured as described previously.
FIG. 2. The effect of continuous exposure of HIV-infected cells to A-77003
at concentrations 4-, 8-, and 16-fold the EC50. Four bioreactors were set with 107
CEM cells and 105 CEM-H9IIIB cells (infected-to-uninfected ratio, 1:100). The
A-77003-treated bioreactors and untreated unit were set in parallel, and the cells
were continuously exposed to medium with (0.5 [1], 1 [h], and 2 [] mM
A-77003) and without (n) the drug. Samples were taken from the ECS at the
indicated time points, and p24 in the cell-free culture medium was measured as
described previously.
FIG. 3. Analysis of unintegrated HIV-1 DNA by PCR. DNA was prepared
on days 3, 5, and 7 of treatment by the Hirt extraction method described in
Materials and Methods. HIV-1 DNA in the Hirt supernatant fraction was am-
plified by PCR with the gag gene-specific primers SK38 and SK39 as described
previously. Lanes M and C contain DNA markers and an HIV-1 control DNA
(100 copies), respectively. Amplification of HIV-1 DNA results in a 115-bp
fragment. A-77003 was used at two times the EC50 (23 EC50), four times the
EC50 (43 EC50), and not at all (No Rx).
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findings and suggest that the spread of HIV was completely
inhibited. The number of p24-positive CEM cells after expo-
sure of the cells to 0.5 mM A-77003 was identical to that of a
1:100 infected-to-uninfected cell mixture at baseline. In con-
trast, cells grown in the parallel untreated bioreactor were
greater than 75% positive for HIV p24 (data not shown).
While these studies were not specifically designed to isolate
HIV resistant to A-77003, we analyzed the EC50 of the virus
harvested from the culture prior to treatment and at day 11
(one and two times the EC50) and at day 15 (four times the
EC50). No significant difference in the sensitivities of the virus
exposed to A-77003 at optimal and suboptimal doses was mea-
sured (data not shown).
Reversal of the antiviral effect. The use of HF bioreactor
cultures permits the rapid change of drug concentration by
removal of the drug from the central reservoir. In a wash-out
experiment, a culture inhibited with 0.5 mMA-77003 for 5 days
was washed free of the drug and both the infectivity and p24
production were measured at 2-h intervals after the removal of
the drug (Fig. 4). Viral p24 released into the medium rose after
2 to 4 h after drug removal, and the yield progressively in-
creased over the next 24 h (Fig. 4). In contrast, infectious HIV
was not isolated from the cultures for 72 h after drug removal
(data not shown).
a1-AGP specifically binds to and inhibits the antiviral activ-
ity of A-77003 in cells acutely and chronically infected with
HIV (2, 4a). The EC50s for A-77003 were increased approxi-
mately 5.6-fold upon the addition of 1 mg of a1-AGP per ml to
cultures initiated at infected-to-uninfected cell ratios of 1:10
and 1:100 (Fig. 5). The point estimate of the EC50 with a1-
AGP has a 95% confidence bound which does not overlap the
95% confidence bound of the point estimate of the EC50 de-
termined in the absence of a1-AGP, which indicates that the
effect of a1-AGP is statistically significantly different. The 95%
confidence bounds for the determinations at infected cell ra-
tios of 1:10 and 1:100 overlap, and there was no statistically
significant effect of increased virus load. Since our in vitro HF
model was designed to expose cells to the drug under physio-
logical conditions, we tested whether a1-AGP added to an
already inhibited (5 days of exposure at 0.5 mM A-77003) HF
culture could bind and reduce the activity of A-77003. a1-AGP
(1 mg/ml) added directly to the ECS reversed the antiviral
effect of A-77003 (0.5 mM). Increased accumulation of p24
(24,994 6 76 pg/ml) was measured in the cell-free tissue cul-
ture medium from the ECS 24 h after the a1-AGP was added.
By comparison, a parallel HF culture with continued drug
exposure had much less accumulation (586 6 68 pg/ml).
DISCUSSION
We have used an HF pharmacodynamic model to determine
the efficacy of A-77003 for HIV infection when it is adminis-
tered as a constant infusion. A mixture of infected and unin-
fected cells was used to mimic the in vivo situation, in which
virus is transmitted to uninfected cells by contact with infected
cells capable of spreading HIV. We have previously shown that
this system could predict the minimum effective dose of an
antiviral agent found by dose-ranging clinical studies (1b). In
this study, we have shown that concentrations of A-77003 at or
above 0.5 mM were required to completely prevent the spread
of HIV in the culture. The ability of A-77003 to prevent de
novo HIV infection was shown by flow cytometric analysis of
cells from the bioreactors. This analysis indicated that mixtures
of infected and uninfected cells exposed to the drug showed a
marked reduction in the number of cells positive for intracel-
lular viral p24 after 7 to 14 days of cocultivation. The virus load
(the percentage of infected cells used to initiate the bioreactor)
did not seem to markedly affect the efficacy of A-77003 in vitro
(Fig. 5) (unpublished data). We have previously shown that
FIG. 4. Removal of A-77003 from treated cultures. An HF bioreactor set
with a 1:100 mixture of HIV-1IIIB-infected and uninfected CEM cells was treated
with 0.5 mM A-77003 for 5 days. At time 0 minus 2 h, the cells were removed
from the ECS, washed twice with drug-containing medium, and returned to the
bioreactor. The cells were removed from the ECS at time 0 and washed twice
with medium without the drug. Concurrently, the medium in the reservoir and
central circulating lines was replaced with drug-free medium. The cells were
returned to the bioreactor and incubated for 2-h periods at the indicated time
points. After the 2-h incubation, cell-free medium was obtained from the ECS
(sample times are in hours) and HIV p24 was measured as described in Materials
and Methods. Error bars indicate standard deviations.
FIG. 5. Effect of a1-AGP on the anti-HIV activity of A-77003 at different
viral loads. Cocultures of CEM-H9IIIB and CEM cells (1:10 [A] and 1:100 [B]
infected-to-uninfected cell ratios) were exposed to the indicated concentrations
of A-77003 in the presence (n) and absence (h) of 1 mg of a1-AGP per ml. At
day 10, the supernatants from the cells were removed and tested for the amount
of p24 as described in Materials and Methods. The graphs show p24 produced by
treated cultures initiated at 1:10 (A) and 1:100 (B) infected-to-uninfected cell
ratios.
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A-77003 was able to block the release of p24 and infectious
virus from chronically infected cells (15). Similar results were
obtained upon measurement of HIV p24 antigen or infectious
virus in cell-free supernatant sequentially removed from the
ECS at various time points. HF bioreactors exposed to effec-
tive concentrations of A-77003 had essentially baseline levels
of HIV p24, while untreated controls had progressively in-
creasing amounts of p24.
Reedijk et al. (23) studied A-77003 in patients treated by
continuous intravenous infusion. Steady-state concentrations
in plasma at the EC50 showed no evidence for antiviral activity.
These clinical data agree with data from our HF pharmacody-
namic studies which suggested that A-77003 would not be
effective when administered as a continuous infusion at the
EC50 (Fig. 1). Furthermore, we ablated the anti-HIV activity of
A-77003 in an experiment in which we added a1-AGP (1 mg/
ml) to an HF culture in which HIV replication was completely
inhibited by continuous exposure to 0.5 mM A-77003. In view
of the potential for avid plasma protein binding of A-77003,
these data predict that A-77003 would not be clinically effica-
cious at steady-state concentrations in plasma that were four-
fold the EC50 in vivo.
Since the HF model system makes it possible to sequentially
monitor the high-density cell population, we examined the cells
at multiple time points after they were exposed to A-77003 at
several dose levels. Both this and earlier studies with 29,39-
didehydro-39-deoxythymidine (D4T) (1b) had indicated that
measurement of HIV proviral DNA in Hirt DNA supernatants
was useful in monitoring viral replication and integration in
vitro. HIV DNA was not detectable in Hirt DNA supernatants
prepared from cells exposed to efficacious concentrations of
A-77003 (at or above 0.5 mM). Synthesis of unintegrated DNA
preceded the release of p24 or infectious HIV into the media
of infected cell mixtures treated with suboptimal amounts of
A-77003, suggesting that unintegrated DNA may be used to
rapidly distinguish effective from non-efficacious doses or
schedules of the drug being tested.
While the population of virus released from cell cultures
which were actively synthesizing HIV DNA contained virus
capable of replicating while exposed to 0.25 mM A-77003,
there was no evidence for selection of virus mutants with al-
tered sensitivity to the protease inhibitor as described previ-
ously (10). While virus resistant to A-77003 was not selected
under the culture conditions and profiles of drug exposure
utilized, the large cell numbers achievable in HF bioreactors
should result in increased numbers of rounds of viral replica-
tion which could favor the selection of resistant virus popula-
tions. The cultures described herein were monitored for only a
limited time period, 11 to 15 days. We are presently involved in
studies to determine whether HIV resistant to protease inhib-
itors would emerge upon culture for extended periods with the
periodic addition of uninfected CEM cells.
The HF model is also useful for performing reversal exper-
iments in which the drug is rapidly removed from the system.
In earlier experiments, p24 production and the spread of HIV
rapidly (,24 h) followed the removal of D4T, a nucleoside
analog, from the cellular milieu (1b). In marked contrast, HIV
p24 release rapidly increased when A-77003 was removed
while the appearance of infectious virus was delayed (.72 h),
suggesting that A-77003 treatment has a potent postantiviral
effect. A recent study by Kageyama et al. also indicated that the
particles produced in the presence of A-77003 had markedly
reduced infectivity and that this was essentially irreversible (9).
It remains to be seen if the postantiviral effect, which results in
the release of noninfectious virus, will permit extensions of the
time required between dosing intervals for A-77003 and other
protease inhibitors. Noninfectious particles released from in-
fected cells treated with these inhibitors may help to elicit
cell-mediated or humoral immune responses. However, cells
treated with protease inhibitors express normal levels of gp120/
160 and still can fuse with uninfected cells, leading to syncy-
tium formation (1a), which may contribute to the continued
loss of CD41 cells.
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